Stavros Stavrakis1,2, Julie A Stoner3, Joel Kardokus4, Paul J Garabelli4,5, Sunny S Po4,5, Ralph Lazzara4,5. 1. Cardiovascular Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. stavros-stavrakis@ouhsc.edu. 2. Heart Rhythm Institute, University of Oklahoma Health Sciences Center, 1200 Everett Drive, TCH 6E103, Oklahoma City, OK, 73104, USA. stavros-stavrakis@ouhsc.edu. 3. Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 4. Cardiovascular Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 5. Heart Rhythm Institute, University of Oklahoma Health Sciences Center, 1200 Everett Drive, TCH 6E103, Oklahoma City, OK, 73104, USA.
Abstract
PURPOSE: We hypothesized that intermittent anticoagulation based on daily rhythm monitoring using the novel oral anticoagulants (NOACs) is feasible and safe among patients with paroxysmal atrial fibrillation (AF). METHODS:Patients with paroxysmal AF and ≥1 risk factors for stroke were randomized to either intermittent or continuous anticoagulation. Those in the intermittent group were instructed to transmit a daily ECG using an iPhone-based rhythm monitoring device. If AF was detected, patients received one of the NOACs for 48 h-1 week. Patients who failed to transmit an ECG for three consecutive days or more than 7 days total were crossed over to continuous anticoagulation. Patients in the continuous group received one of the NOACs. RESULTS:Fifty-eight patients were randomized to either intermittent (n = 29) or continuous anticoagulation (n = 29). Over a median follow-up of 20 months, 20 patients in the intermittent group failed to submit a daily ECG at least once (median three failed submissions). Four patients (14 %) crossed over to continuous anticoagulation due to failure to submit an ECG for three consecutive days. One stroke (continuous group) occurred during the study. Major bleeding occurred in two patients in the continuous and one patient in the intermittent group, after crossing over to continuous anticoagulation. In a prespecified per-protocol analysis, gastrointestinal bleeding was more frequent in the continuous group (16 vs. 0 %; p = 0.047). CONCLUSIONS: Intermittent anticoagulation based on daily rhythm monitoring is feasible and may decrease bleeding in low-risk patients with paroxysmal AF. A larger trial, adequately powered to detect clinical outcomes, is warranted.
RCT Entities:
PURPOSE: We hypothesized that intermittent anticoagulation based on daily rhythm monitoring using the novel oral anticoagulants (NOACs) is feasible and safe among patients with paroxysmal atrial fibrillation (AF). METHODS:Patients with paroxysmal AF and ≥1 risk factors for stroke were randomized to either intermittent or continuous anticoagulation. Those in the intermittent group were instructed to transmit a daily ECG using an iPhone-based rhythm monitoring device. If AF was detected, patients received one of the NOACs for 48 h-1 week. Patients who failed to transmit an ECG for three consecutive days or more than 7 days total were crossed over to continuous anticoagulation. Patients in the continuous group received one of the NOACs. RESULTS: Fifty-eight patients were randomized to either intermittent (n = 29) or continuous anticoagulation (n = 29). Over a median follow-up of 20 months, 20 patients in the intermittent group failed to submit a daily ECG at least once (median three failed submissions). Four patients (14 %) crossed over to continuous anticoagulation due to failure to submit an ECG for three consecutive days. One stroke (continuous group) occurred during the study. Major bleeding occurred in two patients in the continuous and one patient in the intermittent group, after crossing over to continuous anticoagulation. In a prespecified per-protocol analysis, gastrointestinal bleeding was more frequent in the continuous group (16 vs. 0 %; p = 0.047). CONCLUSIONS: Intermittent anticoagulation based on daily rhythm monitoring is feasible and may decrease bleeding in low-risk patients with paroxysmal AF. A larger trial, adequately powered to detect clinical outcomes, is warranted.
Authors: Nicole Lowres; Lis Neubeck; Glenn Salkeld; Ines Krass; Andrew J McLachlan; Julie Redfern; Alexandra A Bennett; Tom Briffa; Adrian Bauman; Carlos Martinez; Christopher Wallenhorst; Jerrett K Lau; David B Brieger; Raymond W Sy; S Ben Freedman Journal: Thromb Haemost Date: 2014-04-01 Impact factor: 5.249
Authors: David T Martin; Malcolm M Bersohn; Albert L Waldo; Mark S Wathen; Wassim K Choucair; Gregory Y H Lip; John Ip; Richard Holcomb; Joseph G Akar; Jonathan L Halperin Journal: Eur Heart J Date: 2015-04-23 Impact factor: 29.983
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2014-03-28 Impact factor: 24.094
Authors: Han S Lim; Scott R Willoughby; Carlee Schultz; Cheryl Gan; Muayad Alasady; Dennis H Lau; Darryl P Leong; Anthony G Brooks; Glenn D Young; Peter M Kistler; Jonathan M Kalman; Matthew I Worthley; Prashanthan Sanders Journal: J Am Coll Cardiol Date: 2013-01-16 Impact factor: 24.094
Authors: Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Giuseppe Boriani; Taya V Glotzer; Massimo Santini; Teena M West; Mirko De Melis; Milan Sepsi; Maurizio Gasparini; Thorsten Lewalter; John A Camm; Daniel E Singer Journal: Eur Heart J Date: 2013-12-11 Impact factor: 29.983
Authors: Agnieszka Kotalczyk; Michał Mazurek; Zbigniew Kalarus; Tatjana S Potpara; Gregory Y H Lip Journal: Nat Rev Cardiol Date: 2020-10-27 Impact factor: 32.419
Authors: Ka Hou Christien Li; Francesca Anne White; Gary Tse; Timothy Tipoe; Tong Liu; Martin Cs Wong; Aaron Jesuthasan; Adrian Baranchuk; Bryan P Yan Journal: JMIR Mhealth Uhealth Date: 2019-02-15 Impact factor: 4.773
Authors: Karim Bayoumy; Mohammed Gaber; Abdallah Elshafeey; Omar Mhaimeed; Elizabeth H Dineen; Francoise A Marvel; Seth S Martin; Evan D Muse; Mintu P Turakhia; Khaldoun G Tarakji; Mohamed B Elshazly Journal: Nat Rev Cardiol Date: 2021-03-04 Impact factor: 32.419
Authors: Venkat D Nagarajan; Su-Lin Lee; Jan-Lukas Robertus; Christoph A Nienaber; Natalia A Trayanova; Sabine Ernst Journal: Eur Heart J Date: 2021-10-07 Impact factor: 29.983